These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Perspectives on clinical trial data transparency and disclosure. Alemayehu D; Anziano RJ; Levenstein M Contemp Clin Trials; 2014 Sep; 39(1):28-33. PubMed ID: 25017444 [TBL] [Abstract][Full Text] [Related]
24. Lower phenytoin serum levels in persons switched from brand to generic phenytoin. Jefferys RJ Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16116145 [No Abstract] [Full Text] [Related]
25. Calls for full disclosure of clinical trials. Frantz S Nat Rev Drug Discov; 2004 Aug; 3(8):635-6. PubMed ID: 15317144 [No Abstract] [Full Text] [Related]
26. Trading on traditional medicines. Basu P Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941 [No Abstract] [Full Text] [Related]
27. NerveCenter: Office of Inspector General warns NIH on lax COI oversight as many academic medical centers look inward. Samson K Ann Neurol; 2010 Mar; 67(3):A7-A10. PubMed ID: 20373337 [No Abstract] [Full Text] [Related]
29. Bioethics, the Surviving Sepsis Campaign and the industry. Bion J; Vincent JL; Angood P Wien Klin Wochenschr; 2006 Feb; 118(1-2):63. PubMed ID: 16489529 [No Abstract] [Full Text] [Related]
30. Bioethics, the Surviving Sepsis Campaign, and the industry. Wiedermann CJ Wien Klin Wochenschr; 2005 Jul; 117(13-14):442-4. PubMed ID: 16091869 [No Abstract] [Full Text] [Related]
31. Biased articles. Friedman JH Med Health R I; 2009 Mar; 92(3):70. PubMed ID: 19385378 [No Abstract] [Full Text] [Related]
32. How to do research fairly in an unjust world. Ballantyne AJ Am J Bioeth; 2010 Jun; 10(6):26-35. PubMed ID: 20526966 [TBL] [Abstract][Full Text] [Related]
33. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan. Honig PK Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231 [TBL] [Abstract][Full Text] [Related]
34. Re: Bioethics, the Surviving Sepsis Campaign, and the industry. Malliani A Wien Klin Wochenschr; 2006 Feb; 118(1-2):63-4. PubMed ID: 16612878 [No Abstract] [Full Text] [Related]
35. Re: Bioethics, the Surviving Sepsis Campaign, and the industry. Mackenzie AF Wien Klin Wochenschr; 2006 Feb; 118(1-2):64. PubMed ID: 16612879 [No Abstract] [Full Text] [Related]
36. Re: Bioethics, the Surviving Sepsis Campaign, and the industry. Ricevuti G; Gasparetto C Wien Klin Wochenschr; 2006 Feb; 118(1-2):64-5. PubMed ID: 16612880 [No Abstract] [Full Text] [Related]
37. Re: Bioethics, the Surviving Sepsis Campaign, and the industry. Röggla G; Moser B Wien Klin Wochenschr; 2006 Feb; 118(1-2):65. PubMed ID: 16612881 [No Abstract] [Full Text] [Related]
38. Medical ethics, research and the pharmaceutical industry. Abud-Mendoza C Reumatol Clin; 2012; 8(5):233-5. PubMed ID: 22608694 [No Abstract] [Full Text] [Related]
39. Alterations in processes and priorities needed for new drug development. Wilson JF Ann Intern Med; 2006 Nov; 145(10):793-6. PubMed ID: 17116936 [No Abstract] [Full Text] [Related]
40. Companies facing ethical issue as drugs are tested overseas. Kolata G N Y Times Web; 2004 Mar; ():A1, A15. PubMed ID: 15022671 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]